PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2012-02-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT01082380
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 525
- Registration Number
- NCT01078298
- Locations
- 🇺🇸
Comprehensive Psychiatric Care, Norwich, Connecticut, United States
🇺🇸Clinical Neuroscience Solutions Incorporated, Orlando, Florida, United States
🇩🇪Ludwig Maximilians-Universitaet Muenchen, Muenchen, Germany
Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache
Phase 3
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT01077973
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT01073644
- Locations
- 🇵🇭
Chong Hua Hospital, Cebu City, Philippines
🇵🇭Private Clinic, Manila, Philippines
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 543
- Registration Number
- NCT01073631
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 692
- Registration Number
- NCT01073618
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
Phase 3
Completed
- Conditions
- Growth DisordersIntrauterine Growth Retardation
- Interventions
- Drug: Genotonorm
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 208
- Registration Number
- NCT01073605
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
Completed
- Conditions
- Community-Acquired Bacterial PneumoniaComplicated Skin and Skin Structure InfectionsComplicated Intra-abdominal Infections
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3172
- Registration Number
- NCT01072539
- Locations
- 🇰🇷
Hanil Medical Center, Dobong-Gu, Seoul, Korea, Republic of
🇰🇷Dong-A University Medical Center (Dong-A University Hospital), Busan, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01066546
- Locations
- 🇺🇸
Pfizer Investigational Site, Delray Beach, Florida, United States
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
Phase 2
Withdrawn
- Conditions
- Alzheimer's DiseaseDementiaDimebonInvestigational Drug
- Interventions
- Drug: PF-01913539 5 mgDrug: Placebo
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01066481